Collectively, these data suggest that IFN-γ indeed has anti-SFTSV activity in vivo when used prophylactically, whereas the antiviral activity can be neutralized after SFTSV infection establishment due to the viral antagonism of IFN-γ-STAT1 signaling. The gene discussed is STAT1; the disease is infection.